Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression - Wikidata - awgldk - TriplyDB

Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression

Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression

http://www.wikidata.org/entity/Q34512386

about

Vitamin E, Turmeric and Saffron in Treatment of Alzheimer's Disease Fish oil, lard and soybean oil differentially shape gut microbiota of middle-aged rats.DNA polymerase β deficiency leads to neurodegeneration and exacerbates Alzheimer disease phenotypes.Oxidatively modified nucleic acids in preclinical Alzheimer's disease (PCAD) brain.Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome.Biomarkers of lipid peroxidation in Alzheimer disease (AD): an update.Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment.Dietary oxidized n-3 PUFA induce oxidative stress and inflammation: role of intestinal absorption of 4-HHE and reactivity in intestinal cells.Increased Electron Paramagnetic Resonance Signal Correlates with Mitochondrial Dysfunction and Oxidative Stress in an Alzheimer's disease Mouse Brain 4-Hydroxyhexenal (HHE) impairs glutamate transport in astrocyte cultures Epigenetic changes in the progression of Alzheimer's disease.Oxidative stress in Alzheimer's disease: why did antioxidant therapy fail?Nucleic acid oxidation: an early feature of Alzheimer's disease.Dietary lipids and their oxidized products in Alzheimer's disease.The Role of PICALM in Alzheimer's Disease.Chronic oxidative damage together with genome repair deficiency in the neurons is a double whammy for neurodegeneration: Is damage response signaling a potential therapeutic target?Astrocyte dysfunction in Alzheimer disease.Deuterium-reinforced polyunsaturated fatty acids improve cognition in a mouse model of sporadic Alzheimer's disease.Vitamin E supplementation modulates the biological effects of omega-3 fatty acids in naturally aged rats.Deuterated polyunsaturated fatty acids reduce brain lipid peroxidation and hippocampal amyloid β-peptide levels, without discernable behavioral effects in an APP/PS1 mutant transgenic mouse model of Alzheimer's disease.Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease.A Bifunctional Anti-Amyloid Blocks Oxidative Stress and the Accumulation of Intraneuronal Amyloid-Beta Suppression of Presymptomatic Oxidative Stress and Inflammation in Neurodegeneration by Grape-Derived Polyphenols

P2860

Q28080306-6747979D-D8F4-49DD-9DEB-4ECDC3519A03 Q33678431-51CF7635-4BE1-43BF-99EF-F3A68D8E0C18 Q35098038-E3E3D94F-DE32-4AEA-94BC-3911AB9A4C2D Q35286714-C5103059-357F-40CA-BC2D-2264801999F0 Q35677159-317920A3-B048-4C81-A22D-E96711E1B24F Q35738877-8FB25F68-C7A4-4DD8-9606-8DE5FAEA8D02 Q36041047-8076650F-1CF1-4B64-B7A0-B664F1C696D8 Q36213850-4D349D19-BBF9-46EE-9A6D-DA4F361A130F Q36820939-C3405826-6138-4A80-AAF3-5577AFF9220A Q36821506-5F93327C-7C29-4DB3-895A-BCC896F356A7 Q37378037-D614FE76-799A-4BA9-B62F-89DDDA999EE5 Q37616153-6E4B1DF9-E6EA-47A5-B48C-024689275D6D Q37626224-F6DD3BFC-AD40-425A-B680-DCE86CC0ECCA Q37939806-8C629A4B-19FE-4D59-A0DD-4E824A9695D0 Q38245888-3237BFC5-C2CB-45B7-841E-C1D99DFE6136 Q38963019-541DC9FE-E875-488A-A46D-4AD03C74DECF Q39280590-4A695E0F-F33A-41E2-8FFC-33B37975D330 Q46287807-BDAE0687-A417-4839-B879-0F634FCD4AEF Q48389172-1D9A6A7A-7951-45F5-84B4-3AE485FB96D2 Q51759414-81AE4BE5-6C21-451F-A54E-888E721B0B95 Q54996405-738A791F-6D69-4B5F-8F6A-91A778B536F6 Q58697561-8AB0C040-A17E-4E07-8000-29094A006C15 Q58697995-EAADF0FD-51D7-4F0B-BE0B-5E5C77BBFAE7

P2860

Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression

http://www.wikidata.org/entity/Q34512386

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression

@ast

Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression

@en

Elevated 4-hydroxyhexenal in Alzheimer's disease

@nl

type

label

Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression

@ast

Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression

@en

Elevated 4-hydroxyhexenal in Alzheimer's disease

@nl

prefLabel

Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression

@ast

Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression

@en

Elevated 4-hydroxyhexenal in Alzheimer's disease

@nl

P1433

Q34512386-F46D4BC7-755C-416A-B107-25BED9244EE4

P1476

Q34512386-F3DF2E14-A360-402E-8EB1-B39FB43593C0

P2093

Q34512386-023778EB-F450-46FE-A66A-FF3FEA0283DC

Q34512386-05F7BC38-2FC8-4334-B852-90534A43246B

Q34512386-64863D05-5E20-4FB3-BFE6-E7F342755251

Q34512386-FCCD022C-6FBB-49D7-91B7-761A747CDEC4

P2860

Q34512386-00522B48-3D65-480C-B2D9-D7F8F6B2A3AB

Q34512386-061721DD-6CA8-4EFF-9BE3-A276B254D41E

Q34512386-09F9460E-2BA0-4E20-9FFB-8834AA1EA921

Q34512386-0B6824F7-6C85-46F0-942D-304F068273BB

Q34512386-0E899C48-C01F-4EC4-AF71-5DB8FBAC424E

Q34512386-0F07DFF9-0DF4-48A6-9AEE-687E2D328BD2

Q34512386-1112A11C-5092-4F33-950E-DC5D16C03B53

Q34512386-1164CD8C-4C86-4FB8-914D-F54866304817

Q34512386-125CD211-A563-469D-9B44-60533DD300A5

Q34512386-1909B29F-41D3-40E1-9ED9-95011F8ACF68

P304

Q34512386-64B6A650-CC33-4B92-A724-581F94FF8DB2

P31

Q34512386-0A42E50B-0FBF-48D0-B00F-A914E37EC397

P356

Q34512386-08CE757E-6139-4819-B948-2CA4E616843D

P433

Q34512386-FC1B551E-73F1-43E5-BE25-4E96DBFC8760

P478

Q34512386-7DB549D5-B9A9-4EAE-A45A-7D79ADC379A6

P577

Q34512386-973D7F4F-F996-453A-BF1B-2F638297F394

P5875

Q34512386-FC28DB0A-587D-4485-B3DF-7BD5FED87229

P698

Q34512386-4B81D47D-30A1-4B9E-8FA0-BCD4C055AA3B

P921

Q34512386-3F5A173B-1D8F-465D-89C8-AEE2DE35916D

P932

Q34512386-8E526FFA-CEDA-4CF3-95DB-0A33AC92DCF9

P356

J.NEUROBIOLAGING.2010.08.016

P1433

Neurobiology of Aging

P1476

Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression

@en

P2093

Mark A Lovell

http://www.w3.org/2001/XMLSchema#string

Melissa A Bradley

http://www.w3.org/2001/XMLSchema#string

Shuling Xiong-Fister

http://www.w3.org/2001/XMLSchema#string

William R Markesbery

http://www.w3.org/2001/XMLSchema#string

P2860

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Mild cognitive impairment: clinical characterization and outcome

NF-kappaB activation mechanism of 4-hydroxyhexenal via NIK/IKK and p38 MAPK pathway

Mechanisms of action of docosahexaenoic acid in the nervous system.

Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures.

Induction of endothelial apoptosis by 4-hydroxyhexenal.

Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease.

Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease

Proteomic analysis of oxidatively modified proteins induced by the mitochondrial toxin 3-nitropropionic acid in human astrocytes expressing the HIV protein tat.

P304

1034-1044

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NEUROBIOLAGING.2010.08.016

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P577

2010-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47519403

http://www.w3.org/2001/XMLSchema#string

P698

20965613

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

3025307

http://www.w3.org/2001/XMLSchema#string